Nature Communications

A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial

2026-04-21

Full text

DOI https://doi.org/10.1038/s41467-026-71798-x